Hogan Lovells, the product of last year’s combination of D.C.’s Hogan & Hartson and the U.K.’s Lovells, reported Thursday that post-merger revenue declined slightly, but profits rose as the new firm cut costs.

The Supreme Court on Tuesday granted review in 14 new cases to be argued in its new term. The order list is the product of the Court’s so-called “long conference” Monday at which, in private, it considered the thousands of petitions that have piled up during the summer recess

Generic drug manufacturers are not insulated from lawsuits by an FDA approval process that certifies such drugs as the “bioequivalent” of their brand-name predecessors, a federal judge has ruled. The judge refused to dismiss a suit brought by consumers who were taking Wellbutrin, a brand-name antidepressant, and who claim they had side effects upon switching to a generic. The suit alleges that two drug manufacturers failed to warn the public about differences that affected the release of the product’s active ingredient.

An Oklahoma jury has found the maker of Botox negligent and awarded $15 million to a doctor who says she suffered botulism after using the anti-wrinkle drug.

A new set of court rules that go into effect in California in the New Year offer some of the most significant changes in the field of minors’ personal injury claims in years, lawyers on both sides of the issue say. The rules, the product of two years of negotiation among the plaintiffs bar, defense counsel and judges, address the complex and confusing area of law known as minor’s compromise.